Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

ABRI SCIENCE, LLC

UEI: CMPRHZJGJ3H1CAGE: 8RLZ9

ABRI SCIENCE, LLC is a federal contractor, registered under UEI CMPRHZJGJ3H1 and CAGE code 8RLZ9. It has been awarded $225,000 across 1 federal contract. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

CMPRHZJGJ3H1

CAGE Code

8RLZ9

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

2XLJ

NAICS Codes

325998All Other Miscellaneous Chemical Product and Preparation Manufacturing(Primary)
339999All Other Miscellaneous Manufacturing
541713Research and Development in Nanotechnology
541714Research and Development in Biotechnology (except Nanobiotechnology)
541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ABRI SCIENCE, LLC is a specialized contractor focused on advanced scientific and technical services within the federal sector, operating under NAICS 325998 for other chemical product and preparation manufacturing. The company delivers tailored research, development, and production capabilities in sp...

ABRI SCIENCE, LLC is a specialized contractor focused on advanced scientific and technical services within the federal sector, operating under NAICS 325998 for other chemical product and preparation manufacturing. The company delivers tailored research, development, and production capabilities in specialized chemical formulations, analytical support, and laboratory-scale manufacturing processes critical to defense, homeland security, and public health missions. Their technical expertise includes compound synthesis, material characterization, process validation, and quality control systems aligned with federal regulatory standards, with an emphasis on rapid prototyping and scalable lab-to-field transition. Differentiators include agile R&D workflows, proprietary analytical methodologies, and experience in handling sensitive or regulated substances under controlled environments. Award history is not available to confirm specific agency engagements, but based on their NAICS classification and operational scope, ABRI SCIENCE likely supports agencies requiring advanced chemical solutions such as DHS, DoD, CDC, and NIH—particularly in areas like chemical threat mitigation, diagnostic reagent development, or specialized material synthesis for mission-critical applications. The company’s industry focus centers on high-precision chemical manufacturing and laboratory-based R&D services, serving niche verticals including chemical defense, forensic analysis, and biomedical instrumentation. Their market positioning is that of a responsive, technically agile provider for programs requiring small-batch, high-integrity chemical production and analytical validation, often in time-sensitive or classified contexts. ABRI SCIENCE, LLC is structured as a small business (2L entity) with its primary operations based in Baltimore, Maryland. The company holds no federal certifications, including 8(a), HUBZone, or WOSB, and operates without formal ISO or FedRAMP accreditations. Its geographic footprint is concentrated in the Mid-Atlantic region, with a lean, specialized workforce optimized for technical execution rather than large-scale contract management. The firm positions itself as a nimble technical partner for agencies seeking precise, non-commodity scientific services.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$225.0K100%
Awards by NAICS
- Unknown NAICS$225.0K100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in ABRI SCIENCE, LLC's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Department of Health and Human Services

POSTED

3 months ago

DEADLINE

in 8 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Department of Health and Human Services

POSTED

3 months ago

DEADLINE

in 8 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Department of Health and Human Services

POSTED

3 months ago

DEADLINE

in 8 months
View Details